Research
-
Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers
Schaeffer Center experts propose two different types of payment models applicable to disease-modifying therapies in Alzheimer’s disease, and suggest four strategies to overcome challenges in their implementation.
Categorized in -
Messages in Prescription Drug Advertising for Four Chronic Diseases, 2003-2016: A Content Analysis
Examining the frequency and content of messages related to pharmacological and evidence-based, non-pharmaceutical treatments in direct-to-consumer advertising (DTCA) for prescription drugs treating four chronic diseases in the United States.
Categorized in -
Quality of Survey Responses at Older Ages Predicts Cognitive Decline and Mortality Risk
It is widely recognized that survey satisficing, inattentive, or careless responding in questionnaires reduces the quality of self-report data.
Categorized in -
Assessing the Use of Data Systems to Estimate Return-on-Investment of Behavioral Healthcare Interventions: Opportunities and Barriers
America is facing a behavioral health crisis, both in terms of increasing prevalence rates and high behavioral healthcare needs.
Categorized in -
The Relationship Between Multimorbidity and Types of Chronic Diseases and Self-Rated Memory
This study explores the impact of multimorbidity and types of chronic diseases on self-rated memory in older adults in the United States.
Categorized in -
Frameworks for Protecting Workers and the Public from Inhalation Hazards
A National Academies committee will consider the oversight and regulatory processes needed to ensure the public and such workers have access to effective respiratory protective devices and guidance on their use to mitigate exposures to inhalation hazards—including those arising during disasters and public health emergencies.
-
The Economic Case for Federal Investment in COVID-19 Vaccines and Therapeutics Remains Strong
Schaeffer Initiative experts argue that there is a strong economic case for continued federal investment in COVID-19 vaccines and therapeutics.
-
Shifting the Demand for Vaccines: A Review of Strategies
Vaccines prevent millions of deaths, and yet millions of people die each year from vaccine-preventable diseases. The primary reason for these deaths is that a significant fraction of the population chooses not to vaccinate. Why don’t people vaccinate, and what can be done to increase vaccination rates besides providing free and easy access to vaccines?
Categorized in -
Trends and Disparities in the Utilization of Influenza Vaccines Among Commercially Insured US Adults During the COVID-19 Pandemic
Researchers attempted tp under how COVID-19 affected influenza vaccine utilization and disparities.
Categorized in -
Impact of Non-Binding FDA Guidances On Primary Endpoint Selection in Alzheimer’s Disease Trials
Researchers examine the impact of two guidance documents for Alzheimer’s disease (AD) trials. The first guidance in 2013 encouraged the use of cognitive/functional endpoints, while the second in 2018 modified such recommendation.